The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
 
Jean-Philippe Zurcher
No Relationships to Disclose
 
Morgan Goujon
Honoraria - bms; ipsen
Travel, Accommodations, Expenses - Pfizer
 
Paul H. Cottu
No Relationships to Disclose
 
Isabelle Desmoulins
No Relationships to Disclose
 
Luis Teixeira
Consulting or Advisory Role - Lilly
Research Funding - Novartis
 
Laura Mansi
No Relationships to Disclose
 
Guillaume Meynard
No Relationships to Disclose
 
Erion Dobi
Travel, Accommodations, Expenses - Pfizer
 
Elise Rowinski
No Relationships to Disclose
 
Marion Stacoffe
No Relationships to Disclose
 
Paule Augereau
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Novartis/Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; GlaxoSmithKline; Novartis/Pfizer
 
Marie Robert
No Relationships to Disclose
 
Yann Mottaz
No Relationships to Disclose
 
Anaïs Gaiffe
No Relationships to Disclose
 
Aurélie Grandvuillemin
No Relationships to Disclose
 
Mapi Fleury
No Relationships to Disclose
 
Ana Dolcan
No Relationships to Disclose
 
Athina Stravodimou
No Relationships to Disclose
 
Khalil Zaman
Consulting or Advisory Role - AstraZeneca/MedImmune; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Lilly O.; MSD; Novartis; Pierre Fabre; Seagen
Research Funding - Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Pharmaceutical; Gilead Sciences; Pierre Fabre; Roche
(OPTIONAL) Uncompensated Relationships - Pierre Fabre
 
Elsa Curtit
Honoraria - Daiichi Sankyo Pharmaceutical; Genomic Health
Travel, Accommodations, Expenses - AstraZeneca; Novartis